EMA panel recommends approval of Bluebird Bio's first gene therapy

A European Medicines Agency panel on Friday recommended a conditional marketing approval for a gene therapy from Bluebird Bio Inc as a genetic blood disorder treatment, setting the stage for the U.S. biotech to win its first regulatory nod.

from Reuters: Health https://ift.tt/2OvtdBV
via IFTTT

• Tweet
• Share
• Share
• Share
• Share